Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This drug is a fixed-dose combination of three active ingredients—diclofenac, acetaminophen (also known as paracetamol), and codeine—used for the management of moderate to severe pain. Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that works by inhibiting cyclooxygenase enzymes (COX-1 and COX-2), thereby reducing prostaglandin synthesis, which leads to decreased inflammation and pain[3][6][8]. Acetaminophen acts primarily in the central nervous system to inhibit prostaglandin synthesis, providing analgesic and antipyretic effects[1][5]. Codeine is an opioid analgesic that exerts its effect mainly through conversion to morphine via CYP2D6-mediated metabolism; it binds to mu-opioid receptors in the central nervous system, increasing pain threshold and altering pain perception[4][7]. The combination leverages different mechanisms of action for superior analgesia compared with individual components or dual combinations. Clinical studies have shown this triple combination provides enhanced pain relief after procedures such as dental surgery but may increase the risk of side effects due to additive adverse event profiles from each component[2][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on diclofenac + acetaminophen + codeine.